Maisonneuve-Rosemont Hospital Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2013
NCT01942460
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Dr. Jean-Sebastien Delisle, MD, PhD

Active Ingredients

Drugs in Phase 4 Trials (1)

ferumoxytol (feraheme) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Epstein-Barr Virus Infections (Phase 2)

Infections (Phase 2)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Lymphoproliferative Disorders (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1